A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1200

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: IV Tulisokibart
DRUG: SC Tulisokibart
OTHER: IV Placebo
OTHER: SC Placebo

Sponsor

Merck Sharp & Dohme LLC